1 The potential of SARS-CoV-2 antigen-detection tests in

2 the screening of asymptomatic persons

)

aul Schnitzler ¹ , Klaus Heeg ¹ ,
ıl, Heidelberg, Germany
pical Diseases, London School
elberg, Germany
eld, positive predictive value
Tel.: <u>+49 6221 56-22999</u>
Im Neuenheimer Feld 324,
diagnostic tests (Ag-RDTs) for
l screening of asymptomatic
1

24 individuals.

25	Methods: This study presents data from a pragmatic implementation study for universal Ag-
26	RDT-based screening at a tertiary care hospital in Germany where all incoming patients
27	without symptoms suggestive of SARS-CoV-2 were screened with an Ag-RDT prior to
28	admission since October 2020.
29	Results: In total, 49,542 RDTs were performed in 27,199 asymptomatic individuals over a
30	duration of five months. Out of 222 positive results, 196 underwent in-house confirmatory
31	testing with PCR, out of which 170 were confirmed positive, indicating a positive predictive
32	value (PPV) of 86.7%. Negative Ag-RDTs were not routinely tested with PCR, but a total of
33	94 cases of false negative Ag-RDTs were detected due to PCR tests being performed within
34	the following five days with a median CT-value of 33.
35	Conclusions: This study provides evidence that Ag-RDTs can have a high diagnostic yield
36	for transmission relevant infections with limited false-positives when utilized at the point of
37	care on asymptomatic patients and thus can be a suitable public-health test for universal

38 screening.

39 Introduction

40 Several researchers and policy makers, supported by evidence from modelling studies, have 41 recently argued to increase large-scale screening for SARS-CoV-2 to curb transmission from 42 patients with minimal or no symptoms. [1–5] Antigen-detection point-of-care rapid diagnostic 43 tests (Ag-RDTs) have shown very good sensitivity (88%) in persons with high viral load (CT 44 <30) along with high specificity (>99%).[6, 7] With their favourable ease-of-use, rapid turn-45 around, and good (although suboptimal) performance, Ag-RDTs meet the characteristics for a 46 test for public health use and could allow for better control of transmission if implemented in 47 well-designed universal screening strategies.[8, 9] However, one frequently raised concern 48 has been the potentially insufficient specificity, leading to large numbers of false-positives 49 when using Ag-RDTs in large-scale screening strategies with low prevalence, which could 50 conceivably disrupt workflows and undermine trust in the test. Furthermore, in a setting 51 where high-risk persons are present (e.g., hospital), concerns exist regarding imperfect 52 sensitivity leading to secondary cases and substantial morbidity and mortality. Data from 53 large scale screening implementation efforts that would allow to gauge diagnostic yield and 54 issues with false-positives are limited.

55

56 Methods

We performed a large-scale, pragmatic implementation study of Ag-RDTs in the context of a universal screening program at one of Germany's largest tertiary care hospitals (Heidelberg University Hospital, Germany) serving over 100,000 inpatients and 1.3 million outpatients per year.[10] The study was conducted between 20 September 2020 and 7 March 2021. Patients without SARS-CoV-2 associated symptoms presenting for elective procedures or outpatient treatment requiring close contact or longer presence (e.g., dialysis) were screened with an Ag-RDT. Depending on setting and local SARS-CoV-2 infection dynamics, other

64 external personnel (e.g., craftspeople, visitors, translators) were similarly screened. Trained 65 nursing staff performed the STANDARD Q COVID-19 Ag Test (SD Biosensor, Inc. 66 Gyeonggi-do, Korea), a WHO recommended and independently validated instrument-free 67 lateral flow assay for SARS-CoV-2 detection,[11] using nasopharyngeal swabs. In patients 68 with a positive Ag-RDT, an additional nasopharyngeal swab was collected for confirmatory 69 SARS-CoV-2 PCR. Ag-RDT results were confirmed with PCR in selected departments prior 70 to ward admission (e.g., haematology), prior to planned procedures associated with high 71 levels of aerosol production, or when a patient developed SARS-CoV-2 associated symptoms 72 or a cluster of cases occurred. To analyse diagnostic yield of Ag-RDTs and false positives, 73 we systematically extracted results of the Ag-RDTs, as well PCR-tests (with CT values) that 74 were done within 5 days after Ag-RDT screening. PPV and sensitivity were computed using 75 the confirmatory PCR result as reference standard. Analysis was conducted using R v4.0.3 76 (The R Foundation). The ethical review board at Heidelberg University approved this study 77 (S-811/2020). PPV and sensitivity were computed using the confirmatory PCR result as 78 reference standard.

79

80 **Results**

Between 20 September 2020 and 7 March 2021, 49,542 Ag-RDTs were performed in 27,421 asymptomatic individuals. Ag-RDTs were positive in 222 individuals and 49,320 Ag-RDTs were negative in 27,199 individuals. Out of the 222 individuals with positive Ag-RDTs, 196 (88.3%) were also tested using PCR in-house. The PPV for the Ag-RDTs was 170/196 (86.7%, 95%CI 81.2-91.1%). Among patients with a positive confirmatory PCR performed within 5 days of a positive Ag-RDT, the median CT value was 19 (IQR 15-24, Figure 1). Of 27,421 patients with a negative Ag-RDT, 94 had a positive PCR in the 5 days following

the Ag-RDT. The median number of days between the tests was 1 (IQR 0-1). Based on these


medRxiv preprint doi: https://doi.org/10.1101/2021.06.07.21258465; this version posted June 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

89 false-negative cases identified via PCR, the overall sensitivity of the Ag-RDT can be 90 estimated to be 170/264 (64.4%, 95%CI 58.3-70.2). The median CT value of patients who 91 were missed using Ag-RDTs was 33 (IQR 29-35). In total, only 12/94 (12.8%) Ag-RDT 92 false-negative patients had a PCR with a CT-value <25, and 10/12 were identified on the 93 same or following day.

94

95 Figure 1. SARS-CoV-2 PCR CT-values according to Ag-RDT result (left) and for false-

96 negative Ag-RDT results according to the number of days between discordant tests (right).



98



100 This pragmatic implementation study of a universal screening programme of asymptomatic 101 patients at a tertiary care hospital showed the benefit of Ag-RDTs identifying SARS-CoV-2 102 infected persons who would have otherwise entered a high-risk environment leading to 103 potential secondary transmission. The sensitivity observed in this study is higher than that 104 observed in other studies of asymptomatic infections.[7] Although the data on accuracy in 105 asymptomatic patients is limited, we acknowledge that the sensitivity estimate is likely an

106 overestimate, as not all patients with asymptomatic infections were PCR-tested in this 107 pragmatic study. However, the study confirms that most cases at high-risk of causing 108 secondary infections are detected via Ag-RDT. Missed cases with CT<25 on PCR testing 109 were mostly captured within 24hrs and are likely attributable to a negative Ag-RDT in the 110 early phase of disease when the viral load is increasing rapidly.[12] Furthermore, the study 111 showed a very high PPV of the Ag-RDT, thus confirming the high reliability of a positive 112 result on an Ag-RDT shown in accuracy studies.[7] 113 To the best of our knowledge, this is the first large-scale implementation study of a universal 114 screening program of asymptomatic individuals to analyse the diagnostic yield of Ag-RDTs. 115 The central limitation of this study, inherent to a pragmatic implementation study, is the 116 limited confirmatory PCR testing for negative Ag-RDTs.

117 In conclusion, this study provides evidence that an Ag-RDT can be a suitable test for large-

scale universal screening in a hospital setting and add the important component of a public-

119 health test to our diagnostic armamentarium.

120

121 Conflict of interest statement

122 Mr Wachinger, Dr. Olaru, Mrs Horner, Dr. Schnitzler, and Dr. Heeg have nothing to disclose;

123 Dr. Denkinger reports grants from Ministry of Science, Research and Culture, State of Baden

124 Wuerttemberg, Germany, during the conduct of the study.

125

126 Funding

127 This study was funded in part by the Ministry of Science, Research and the Arts of Baden-

128 Württemberg, Germany, as well as hospital-internal funds

129

130 Acknowledgments

6

131	Non	e				
132						
133	Author's Contributions					
134	JW, KH, and CMD conceptualized the study. IDO analysed the data, supported by JW, SH,					
135	PS, a	and CMD. JW, IDO, and CMD drafted the manuscript. All co-authors critically revised				
136	and approved the final version of the letter.					
137						
138	Refe	erences				
139	1	Johnson-León M, Caplan AL, Kenny L, et al. Executive summary: It's wrong not to test:				
140		The case for universal, frequent rapid COVID-19 testing. EClinicalMedicine				
141		2021;33:100759. doi:10.1016/j.eclinm.2021.100759 [published Online First: 19				
142		February 2021].				
143	2	Moghadas SM, Fitzpatrick MC, Sah P, et al. The implications of silent transmission for				
144		the control of COVID-19 outbreaks. Proc Natl Acad Sci USA 2020;117(30):17513–15.				
145	3	World Health Organization. SARS-CoV-2 antigen-detecting rapid diagnostic tests: an				
146		implementation guide 2020. Available at:				
147		https://www.who.int/publications/i/item/9789240017740 Accessed April 28, 2021.				
148	4	Smith DRM, Duval A, Pouwels KB, et al. Optimizing COVID-19 surveillance in long-				
149		term care facilities: A modelling study. BMC Med 2020;18(1):386.				
150		doi:10.1186/s12916-020-01866-6 [published Online First: 8 December 2020].				
151	5	Peeling RW, Olliaro P. Rolling out COVID-19 antigen rapid diagnostic tests: The time				
152		is now. The Lancet Infectious Diseases 2021;214:836.				
153	6	Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based				
154		tests for diagnosis of SARS-CoV-2 infection. Cochrane Database of Systematic				
155		Reviews 2021;59(1):e01262.				

156	7	Brümmer LE, Katzenschlage	er S.	Gaeddert M, et al.	The accurac	y of novel	antigen	rapid

- 157 diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. medRxiv
- 158 2021:2021.02.26.21252546.
- 159 8 Boehme C, Hannay E, Sampath R. SARS-CoV-2 testing for public health use: Core
- 160 principles and considerations for defined use settings. The Lancet Global Health
- 161 2021;9(3):e247-e249.
- 162 9 Larremore DB, Wilder B, Lester E, et al. Test sensitivity is secondary to frequency and
- turnaround time for COVID-19 screening. Sci Adv 2021;7(1).
- doi:10.1126/sciadv.abd5393 [published Online First: 1 January 2021].
- 165 10 Heidelberg University Hospital. Annual Report 2019 2020. Available at:
- 166 https://report.ukhd-mfhd.de/2019/ Accessed April 28, 2021.
- 167 11 Berger A, Nsoga MTN, Perez-Rodriguez FJ, et al. Diagnostic accuracy of two
- 168 commercial SARS-CoV-2 antigen-detecting rapid tests at the point of care in

169 community-based testing centers. PLoS ONE 2021;16(3):e0248921.

- 170 12 Kissler SM, Fauver JR, Mack C, et al. SARS-CoV-2 viral dynamics in acute infections
- 171 2020.
- 172